NCT02665702Unknown2 期
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 76
- 试验地点
- 1
- 主要终点
- Progression Free Survival
研究概览
简要总结
The aim of this study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens
详细描述
This study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens used as second-line treatment of advanced esophageal squamous cell carcinomas
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven primary thoracic esophageal squamous cell carcinoma
- •According to the esophageal AJCC2009 7th to determine new stage IV esophageal cancer
- •The subject has PD after first-line chemotherapy or radiation within a year
- •Presence of at least one index lesion measurable by CT scan or MRI according to RECIST 1.1
- •Can eat more than liquid diet; No signs before esophageal perforation
- •18~75 years
- •Life expectancy of ≥ 3 months
- •ANC ≥ 2×109/L，PLT ≥ 100×109/L，Hb ≥ 90g/L
- •TB ≤ UNL； ALT/AST ≤ 2.5×UNL，AKP ≤ 5×UNL
- •Ccr≤ UNL,Scr≥60 mL/min
- •Normal electrocardiogram (ecg), the body had no unheal wounds
- •Radiotherapy before within the scope of the normal dose and not affect subsequent treatment
- •Prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions
- •Signed written informed consent
排除标准
- •Breast-feeding or pregnant women, no effective contraception if risk of conception exists
- •Chronic diarrhea, enteritis, intestine obstruction which are not under control
- •Esophageal obstruction cannot eat liquid completely, esophagus have deep ulcer perforation or hematemesis; Esophageal cancer common complications such as anastomotic leakage, serious lung complications, etc.
- •A second primary tumor (except skin basal cell carcinoma)
- •The original serious heart disease, including: higher risk of congestive heart failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension
- •With uncontrol nerve, mental illness or mental disorders, compliance is poor, can't cooperate with accounts and response to treatment; Primary brain tumors or CNS metastases illness did not get a control, has obvious cranial hypertension or nerve mental symptoms
- •With bleeding tendency
- •Has inherited bleeding evidence of physical or blood coagulation disorder
- •With clear chemotherapy drug allergy
- •Other researchers believe that patients should not participate in this testing
研究组 & 干预措施
Endostar Combined With NVB and DDP
Experimental
Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
干预措施: NVB (Drug)
Endostar Combined With NVB and DDP
Experimental
Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
干预措施: DDP (Drug)
Endostar Combined With NVB and DDP
Experimental
Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
干预措施: Endostar (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: from the first cycle of treatment (day one) to two month after the last cycle
次要结局
未报告次要终点
研究者
Chang Jian Hua
Chief Physician
Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasEsophageal Squamous Cell CarcinomaNCT03797625Fudan University52
Unknown
3 期
The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC PatientsAngiogenesisBreast CancerNCT02865304Fujian Cancer Hospital80
终止
1 期
Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal DysfunctionRenal DysfunctionCongestive Heart FailureNCT00818701Mayo Clinic1
Unknown
4 期
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)Advanced NSCLCRecurrent NSCLCNCT00813332Simcere Pharmaceutical Co., Ltd300
Unknown
2 期
Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast CancerBreast CancerNCT03907098Zhejiang Cancer Hospital50